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{ In addition to modulating insulin-like growth factors action, it is now clear that insulin-like growth factor-binding protein-3 also
has intrinsic effects on cell growth and survival. We have compared the effects of insulin-like growth factor-binding protein-3
and transforming growth factor-beta on cell proliferation and death of Hs578T cells and the normal breast epithelial cell line,
MCF-10A. The growth of MCF-10A cells was inhibited at low concentrations of insulin-like growth factor-binding protein-3
but stimulated at high concentrations. These differential effects were unaffected in the presence of an insulin-like growth
factor-I receptor antagonist. A synthetic peptide corresponding to the serine phosphorylation domain of insulin-like growth
factor-binding protein-3 (that does not bind to insulin-like growth factors) also mimicked these differential actions. The growth
of both cell lines was signiﬁcantly inhibited by transforming growth factor-beta, this was associated with a 14-fold increase of
insulin-like growth factor-binding protein-3 secreted by the Hs578T cells but a ﬁve-fold decrease of insulin-like growth factor-
binding protein-3 secreted by MCF-10A cells. Replacement doses of exogenous insulin-like growth factor-binding protein-3
overcame the transforming growth factor-beta-induced growth inhibition in the MCF-10A cells. Cell death induced by
ceramide was signiﬁcantly reduced by insulin-like growth factor-binding protein-3 in the MCF-10A cells and depleting insulin-
like growth factor-binding protein-3 with transforming growth factor-beta in these cells consequently increased their
susceptibility to ceramide. In contrast, insulin-like growth factor-binding protein-3 enhanced apoptosis induced by ceramide in
the Hs578T cells but transforming growth factor-beta treated Hs578T cells were resistant to apoptosis. The addition of anti-
sense mRNA to insulin-like growth factor-binding protein-3 signiﬁcantly abrogated this effect of transforming growth factor-
beta. These data indicate that insulin-like growth factor-binding protein-3 has intrinsic activity capable of inhibiting or enhancing
the growth and survival of breast epithelial cells depending on the cell line and exposure to other cytokines.
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The insulin-like growth factors (IGF)-I and -II are potent mito-
gens acting through the IGF-I tyrosine kinase receptor. The
high afﬁnity IGF-binding proteins (IGFBP) modulate the avail-
ability of the IGFs to interact with their receptor. In the
circulation, the IGFs are carried mainly by IGFBP-3, which
together with the acid labile subunit (ALS) forms a 150 KDa
complex. This complex serves to prolong the half-life of the
IGFs (Jones and Clemmons, 1995). In addition to the IGF-
dependent functions, it is becoming increasingly clear that the
IGFBPs also possess IGF-independent activity. In the IGF unre-
sponsive breast cancer cell line, Hs578T and the IGF-responsive
normal breast epithelial cell line, MCF-10A, IGFBP-3 can inhibit
cell growth (Oh et al, 1993a; Martin and Baxter, 1999). It has
also been reported that IGFBP-3 alone can induce apoptosis in
prostate cancer cells (Rajah et al, 1997). We have demonstrated
previously that IGFBP-3 did not induce apoptosis alone but
could accentuate cell death induced by triggers of apoptosis
such as a ceramide analogue (C2) (Gill et al, 1997), Antimycin
A (Perks et al, 2000a), UV radiation (Hollowood et al, 2000a),
gamma radiation (Williams et al, 2000) and paclitaxel (Fowler
et al, 2000), but had no effect on cell death induced by an
arg-gly-asp (RGD)-containing disintegrin (Perks et al, 1999).
The mechanism by which IGFBP-3 can induce these IGF-inde-
pendent actions is still unclear. There have been reports of a
putative IGFBP-3 receptor (Oh et al, 1993b), and that IGFBP-
3 can interact with mitogen activated protein kinase (MAP
kinase) signalling (Martin and Baxter, 1999). We demonstrated
previously that treatment with IGFBP-3 resulted in a rapid
dephosphorylation of focal adhesion kinase (FAK) that associates
with activated integrin receptors (Perks and Holly, 1999) as well
as inhibiting cell adhesion of Hs578T cells to an extracellular
matrix (Perks et al, 2000b).
Transforming growth factor-beta (TGF-b) is a cytokine that
regulates cell growth, differentiation, morphogenesis and apopto-
sis. TGF-b is a growth stimulator of ﬁbroblast cells but is growth
inhibitory in breast epithelial cells and mammary tumours
(Daniel et al, 1996; Gold, 1999). Growth inhibitors such as
TGF-b, retinoic acid and vitamin D (Colston et al, 1998) are
potent regulators of IGFBP-3 and can stimulate IGFBP-3 at the
mRNA level. TGF-b-induced growth inhibition seen in Hs578T
breast cancer cells, as well as the TGF-b-induced proliferation
seen in colon cancer cells and human airway smooth muscle cells
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www.bjcancer.comis at least partially mediated by IGFBP-3 (Oh et al, 1995; Cohen
et al, 2000; Kansra et al, 2000). The relationship between IGFBP-
3 and TGF-b also extends to the receptors and the signalling
pathways. There have been reports that the type V TGF-b recep-
tor maybe a putative IGFBP-3 receptor (Leal et al, 1997) and
that IGFBP-3 may interact with the SMAD signalling proteins
and the type II TGF-b receptor to induce its growth inhibitory
actions (Fanayan et al, 2000).
In this study we looked at the effects of IGFBP-3 on cell growth
and death in the normal breast epithelial cell line, MCF-10A and
compared the effects of TGF-b on the growth, death and the
production of IGFBP-3 in these cells to that in the Hs578T breast
cancer cell line.
MATERIALS AND METHODS
Materials
Recombinant human non-glycosylated IGFBP-3 (ngIGFBP-3) was
a kind gift from Dr C Maack (Celtrix, CA, USA). Human
recombinant IGF-I was purchased from Gropep (Adelaide,
Australia). The ceramide analogue, C2, was purchased from
Calbiochem (Nottingham, UK). The IGF-1 receptor antagonist
(IGFIR-AT) was purchased from Immunological and Biochemical
Testsystems (IBT) GmbH (Reutlingen, Germany). The IGFIR-AT
is an IGF-I peptide analogue that acts as a competitive ligand to
block receptor autophosphorylation. It has been shown to inhibit
the proliferation of a number of cell lines in a dose-dependent
manner. This peptide JB1 was prepared according to the
sequence described by Pietrzkowski et al (1992): H-CYAAPLK-
PAKSC-NH2. In the normal MCF-10A cells, the concentration
of the IGFIR-AT used (100 ng ml
71) did not have any effect
on basal, unstimulated cell proliferation whereas concentrations
of 120 ng ml
71 and above inhibited cell proliferation (data not
shown). Human recombinant transforming growth factor-beta1
(TGF-b) and all other chemicals were purchased from Sigma
(Poole, UK). Tissue culture plastics were obtained from Greiner
Labortechnik Ltd (Stonehouse, UK). Serine phosphorylation
domain (SPD) peptide is a 15 amino acid peptide sequence
spanning the two mid-region serines of IGFBP-3. It was synthe-
sised at the microchemical facility of the Babraham Institute
(Cambridge, UK). We have demonstrated previously that of 17
peptides corresponding to different regions of IGFBP-3, SPD
was the only one which was able to mimic the actions observed
with full length IGFBP-3 on cell death. In addition SPD had no
interaction with IGF-I (Hollowood et al, 2000b). The IGFBP-3
antisense oligodeoxynucleotide was prepared by the Department
of Biochemistry, University of Bristol (Bristol, UK). The
IGFBP-3 antisense mRNA was complementary to 20 nucleotides
that encode the N-terminus of human IGFBP-3 and had the
sequence 5'-CAT GAC GCC TGC AAC CGG GG-3' (positions
2021–2040); the sequence of the sense mRNA was 5'-CCC
CGG TTG CAG GCG TCA TG-3'.
Cell culture
Human breast cancer cells, Hs578T were purchased from ECACC
(Porton Down, Wiltshire, UK) and grown in humidiﬁed 5% carbon
dioxide atmosphere at 378C. The cells were cultured in Dulbecco’s
modiﬁed Eagles Medium (DMEM) with glutamax-1 supplemented
with 10% foetal calf serum (FCS), penicillin (500 iu ml
71), strepto-
mycin (5 mg ml
71) and L-glutamine (2 nM) –growth media
(GM). The MCF-10A cells are a spontaneously immortalised breast
epithelial cell line that maintain a relatively normal phenotype in
that they (a) lack tumourgenicity in nude mice, (b) exhibit 3D
growth in collagen, (c) their growth was controlled by hormones
and growth factors and (d) they form domes in conﬂuent cultures
(Soule et al, 1990). These cells were purchased from ATCC (Mana-
ssas, VA, USA) and grown in humidiﬁed 5% carbon dioxide
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Figure 1 Differential, IGF-independent effects of IGFBP-3 on growth of
MCF-10A cells. Graphs represent the per cent of cells relative to control.
Cells were treated (A) with increasing doses of ngIGFBP-3 for 24 h (where
P50.05*; P50.01**; P50.001*** relative to the control (CT)), or (B)
with IGF-1 (100 ng ml
71) or IGFBP-3 with or without the IGFIR-AT
(where ***IGF-I4CT and IGFBP-3 (100 ng ml
71)4CT; P50.001,
**IGF-I+IGFIR-AT5IGF-I; P50.01, *IGFBP-3 (20 ng ml
71)5CT;
P50.05). Graph represents the mean of experiments that were each per-
formed in triplicate at least three times.
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Figure 2 The effects of the SPD peptide on growth of MCF-10A cells.
Graphs represent per cent of cells relative to the control. Cells were
treated with increasing doses of SPD for 24 h where P50.05*;
P50.01**; P50.001*** relative to control (CT). Graph represents the
mean of experiments that were each performed in triplicate at least three
times.
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DMEM:Hams Nutrient Mix F12 media supplemented with 5%
horse serum (HS), penicillin (500 iu ml
71), streptomycin
(5 mg ml
71), L-glutamine (2 nM), cholera toxin (100 ng ml
71),
insulin (10 mgm l
71), EGF (20 ng ml
71) and hydrocortisol
(0.5 mgm l
71). Experiments for both cell lines were performed in
phenol red-and serum-free 1:1 mixture of DMEM:Hams Nutrient
Mix F12 supplement with sodium bicarbonate (0.12%), bovine
serum albumin (BSA) (0.2 mg ml
71), transferrin (0.1 mg ml
71),
penicillin (500 iu ml
71), streptomycin (5 mg ml
71) and L-gluta-
mine (2 nM) (SFM).
Cell dosing protocol
The MCF-10A cells were seeded in six well plates and grown in GM
for 24 h. Cells were either (a) switched to SFM for 48 h before
dosing with ngIGFBP-3 or SPD for 24 h, (b) switched to SFM for
24 h before dosing with TGF-b for 3 days with a co-incubation with
an apoptotic dose of C2 ceramide (25–35 mM) on the penultimate
day; (c) switched to SFM for 24 h before dosing with TGF-b and
ngIGFBP-3 as described in ﬁgure legends; or (d) switched to SFM
for 24 h prior to a pre-incubation with ngIGFBP-3 for 24 h
followed by a co-incubation with an apoptotic dose of C2-ceramide.
The Hs578T breast cancer cells were seeded in six well plates in
GM for 24 h prior to switching to SFM for a further 24 h. Cells
were: (a) pre-incubated with IGFBP-3 (100 ng ml
71) for 24 h
followed by a co-incubation with an apoptotic dose of C2; or
(b) dosed with TGF-b in low serum (2%) media for 5 days with
or without 20 mgm l
71 anti-sense or sense mRNA to IGFBP-3
on days 1, 3 and 5 followed by a co-incubation on the penultimate
day with an apoptotic dose of C2-ceramide (20–30 mM). The ﬁnal
dose used in each experiment was dependent on the conﬂuency
and passage number of the cells.
Trypan blue dye exclusion
Aliquots of cells were loaded onto a haemocytometer (1:1) with
Trypan blue. Viable cells exclude the dye. Both living and dead
cells were counted, from which the percentage dead cells or percen-
tage of cells relative to the control were calculated.
Flow cytometry
This technique was used to determine the amount of apoptosis in
any given sample. The fragmented DNA of an apoptotic cell has
less capacity to stain than in normal cells and appears as a pre-
G1 peak on a DNA cell cycle histogram. Cells (1–2610
6) were
washed in phosphate buffered saline (PBS) and ﬁxed in 70% etha-
nol for a minimum of 30 min prior to analysis. The ﬁxed cells were
pelleted (6500 r.p.m., 5 min) and washed in PBS. The cells were
resuspended in 500 ml of reaction buffer (propidium iodide,
0.05 mg ml
71; sodium citrate, 0.1%; RNase A, 0.02 mg ml
71;
NP-40, 0.3% pH 8.3). This was incubated for 30 min at 48C prior
to measurement using a FACS Calibur Flow Cytometer (Becton
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
120
100
80
60
40
20
0
%
 
o
f
 
c
e
l
l
s
 
r
e
l
a
t
i
v
e
 
t
o
 
c
o
n
t
r
o
l
Control                   1                        5                       10
Concentration of TGF-b (ng ml
–1)
90
80
70
60
50
40
30
20
10
0
C
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
I
G
F
B
P
-
3
 
(
n
g
 
m
l
–
1
)
Control                   1                       5                      10
Concentration of TGF-b (ng ml–1)
B
A
**
** **
*
Figure 3 The effects of TGF-b on MCF-I0A cell growth and IGFBP-3
production. Graphs represent (A) the per cent of cells relative to the
control and (B) total concentration of IGFBP-3 (ng ml
71). MCF-10A cells
were treated with increasing doses of TGF-b for 3 days where P50.01**
relative to control (CT). Conditioned media was collected and IGFBP-3 le-
vels were measures using RIA where P50.05* relative to control. Graph
represents the mean of experiments that were each performed in triplicate
at least three times.
120
100
80
60
40
20
0
%
 
o
f
 
c
e
l
l
s
 
r
e
l
a
t
i
v
e
 
t
o
 
c
o
n
t
r
o
l
Control     0.1        0.5          1           5          10         20         30
Concentration of TGF-b (ng m–1)
*
800
700
600
500
400
300
200
100
0
C
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
I
G
F
B
P
-
3
 
(
n
g
 
m
l
–
1
)
CT        0.1        0.5          1           5          10           20         30
Concentration of TGF-b (ng m–1)
***
***
***
***
***
***
***
A
B
Figure 4 The effects of TGF-b on Hs578T cell growth and IGFBP-3 pro-
duction. Graphs represents (A) the per cent of cells relative to the control
and (B) the total concentration of IGFBP-3 (ng ml
71). Hs578T cells were
treated with increasing doses of TGF-b in low serum media for 5 days
(where P50.05*; P50.001*** relative to control). Conditioned media
was collected and IGFBP-3 levels were measures using RIA. Graph repre-
sents the mean of experiments that were each performed in triplicate at
least three times.
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tation. Analysis was by Cell Quest software package (Becton
Dickinson).
Radioimmunoassay
Levels of IGFBP-3 in conditioned media were measured by radio-
immunoassay as previously described (Yateman et al, 1993).
The basal levels of IGF-I and -II produced by both the MCF-
10A and the Hs578T cells, as measured by radioimmunoassays
previously described (Taylor et al, 1990; Davies et al, 1991) were
found to be lower than the detection limits of the assays and hence
negligible in relation to the doses required for IGF responses in
these cells (i.e. 51n gm l
71; data not shown).
Statistical analysis
The data were analysed using Microsoft Excel 2000 software pack-
age. Signiﬁcant differences were determined using Students t-test.
Statistically signiﬁcant differences were considered to be present
at P50.05. All graphs represent the mean of experiments that were
each performed in triplicate at least three times+standard error of
the mean.
RESULTS
Differential, IGF-independent effects of IGFBP-3 on
growth of MCF-10A cells
The addition of increasing doses of IGFBP-3 to the MCF-10A cells
resulted in a biphasic response with inhibition of growth at
concentrations of 20 ng ml
71 (P50.001), but enhanced growth
at higher doses of 100 and 200 ng ml
71 (P50.01) (Figure 1A).
To determine whether these effects of IGFBP-3 were IGF-I inde-
pendent we used an IGF-I receptor antagonist (Figure 1B). At
100 ng ml
71, IGF-I signiﬁcantly (P50.001) increased basal cell
number by 41%. The IGF-I receptor antagonist alone had no effect
but on co-incubation with IGF-I, the increase in cell number was
decreased from 141 to 112% (P50.01). As before IGFBP-3 at
low doses signiﬁcantly (P50.05) decreased cell number by 27.8%
and at 100 ng ml
71, signiﬁcantly (P50.001) increased cell number
by 37%. These effects of IGFBP-3 were identical in the presence of
the IGF-I receptor antagonist.
The effects of the SPD peptide on growth of MCF-10A cells
The SPD peptide mimicked the biphasic effect that IGFBP-3
exerted on the growth of MCF-10A cells; with inhibition of growth
at concentrations of 1.5 ng ml
71 (P50.05; molar equivalent to
30 ng ml
71 IGFBP-3), but enhanced growth at concentrations of
5n gm l
71 and above (P50.01; molar equivalent to 100 ng ml
71
and above IGFBP-3) (Figure 2).
The effects of TGF-b on MCF-10A cell growth and
IGFBP-3 production
On MCF-10A cells (Figure 3A), TGF-b dose-dependently inhibited
cell growth with a maximum decrease in cell number of 48.5%
achieved by 5 ng ml
71 (P50.01).
Increasing doses of TGF-b induced a signiﬁcant (P50.05) dose-
dependent decrease in the production of IGFBP-3 with a maxi-
mum decrease of 77% occurring at 10 ng ml
71.
The effects of TGF-b on Hs578T cell growth and
IGFBP-3 production
On Hs578T breast cancer cells, at concentrations of TGF-b of
5n gm l
71 and above, there was a signiﬁcant (P50.05) decrease
in cell growth compared to the control (Figure 4A).
Increasing doses of TGF-b induced a signiﬁcant (P50.001 in
all cases) dose-dependent increase in the production of IGFBP-3
with a maximum 14-fold increase achieved at 10 ng ml
71 (Figure
4B).
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Figure 5 The addition of exogenous IGFBP-3 overcomes TGF-b-in-
duced growth inhibition of MCF-10A cells. Graph shows the per cent of
cells relative to the control. MCF-10A cells were treated with TGF-b
(5 ng ml
71) for 3 days with or without IGFBP-3 (50 ng ml
71) added on
each of the 3 days or IGFBP-3 (150 ng ml
71) added only on day 1 with
TGF-b, (where **IGFBP-3 (50 ng day
71)+TGF-b4TGF-b; P50.01,
*TGF-b5CT; P50.05). Graph represents the mean of experiments that
were each performed in triplicate at least three times.
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Figure 6 The effects of IGFBP-3 and TGF-b on ceramide-induced death
of the MCF-10A cells. Graphs (A + B) represent the per cent of dead cells.
MCF-10A cells were (A) pre-incubated with IGFBP-3 (100 ng ml
71) for
24 h followed by a co-incubation with an apoptotic dose of C2 for a
further 24 h (where ***C24CT; P50.001, *IGFBP-3+C25C2;
P50.05) or (B) treated with TGF-b (5 ng ml
71) for 3 days with or with-
out spiking with an apoptotic dose of C2 on the penultimate day (where
**C24CT; P50.01, *TGF-b+C24C2; P50.05). Graph represents the
mean of experiments that were each performed in triplicate at least three
times.
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TGF-b-induced growth inhibition of MCF-10A cells
Initial experiments, showed that the total amount of IGFBP-3
produced by MCF-10A cells was 150 ng ml
71 after 3 days. Based
on this, exogenous IGFBP-3 was added to replace the TGF-b-deleted
IGFBP-3. Exposure to TGF-b (5 ng ml
71) signiﬁcantly (P50.05)
inhibited cell growth by 30.7% after treatment for 3 days (Figure
5). This inhibition of cell growth by TGF-b was signiﬁcantly
(P50.01) abrogated when IGFBP-3 was added at 50 ng per day.
When 150 ng of IGFBP-3 were added on day one, the inhibition
by TGF-b was insigniﬁcantly reduced, but the daily addition of
IGFBP-3 at 50 ng day was clearly more effective.
The effects of IGFBP-3 and TGF-b on ceramide-induced
death of the MCF-10A cells
Ceramide signiﬁcantly (P50.001) increased cell death compared to
control, while IGFBP-3 alone had no effect. Co-incubation of
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Figure 7 The effect of TGF-b on ceramide-induced death of Hs578T breast cancer cells. Graphs in (A, C and E) represent per cent dead cells while (B)
and (D) represents per cent of cell in pre-G1. Where (A) and (B) Hs578T cells were pre-incubated with IGFBP-3 (100 ng ml
71) for 24 h followed by a co-
incubation of IGFBP-3 and C2 (where C24CT; P50.05 and IGFBP-3+C24C2; P50.05). (C and D) Cells treated with TGF-b in low serum media for 4
days before an apoptotic dose of ceramide was applied (where C24CT; P50.001, TGF-b+C25C2; P50.001 in both cases) or (E) Cells treated with
TGF-b for 5 days in low serum with or without 20 mgm l
71 antisense (AS) or sense (S) mRNA to IGFBP-3 added on days 1, 3, and 5 followed by a
co-incubation of an apoptotic dose of ceramide on day 5, (where ***C2+TGF-b5C2; P50.001, **TGF-b+C2+Antisense4TGF-b+C2; P50.01). Graph
represents the mean of experiments that were each performed in triplicate at least three times.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1963–1969IGFBP-3 and C2 signiﬁcantly (P50.05) decreased cell death
compared to C2 alone (Figure 6A). Identical results were generated
using ﬂow cytometry (data not shown).
We also examined the effects of pre-treating the MCF-10A cells
with TGF-b for 3 days before adding C2 on the penultimate day.
Compared to basal levels, TGF-b (Figure 6B) had no effect on cell
death, while the ceramide analogue (C2) signiﬁcantly (P50.01)
increased cell death from 12 to 26.7%. The addition of C2 to cells
pre-treated with TGF-b signiﬁcantly (P50.01) increased cell death
further to 32.2% in comparison to C2 alone. Identical results were
generated using ﬂow cytometry (data not shown).
The effect of TGF-b on ceramide-induced death of
Hs578T breast cancer cells
Co-incubation of C2 and IGFBP-3 signiﬁcantly (P50.05) increased
cell death compared to C2 alone (Figure 7A). Using ﬂow cytometry
to assess apoptosis generated identical results (Figure 7B). Death of
the Hs578T cells was unaffected by 5 ng ml
71 TGF-b (Figure 7C).
Cell death was signiﬁcantly (P50.001) increased to 70.9 from 9.2%
by C2. Co-incubation of cells with TGF-b and C2 signiﬁcantly
(P50.001) inhibited cell death induced by C2 from 70.9 to
12.4%. Using ﬂow cytometry to assess apoptosis generated identical
results (Figure 7D).
In Figure 7E antisense mRNA to IGFBP-3 was employed to
determine if the protective effect of TGF-b against apoptosis was
mediated by IGFBP-3. Ceramide increased cell death to 42.3%
compared to control levels of 13.9%, while TGF-b alone had no
effect. The co-incubation of TGF-b and C2 resulted in a signiﬁcant
(P50.001) decrease in cell death to 6.8% compared to C2 alone.
The sense and antisense mRNA to IGFBP-3 each alone had no
effect. The survival effect conferred by TGF-b on C2-induced death
was completely abrogated on co-incubation with the antisense
mRNA to IGFBP-3 (P50.01). The addition of TGF-b enhanced
the secretion of IGFBP-3 into the conditioned media from
192 ng ml
71 (untreated cells) to 897 ng ml
71. The presence of
the IGFBP-3 antisense mRNA reduced this to 327 ng ml
71,
although there was also some suppressive effect of the sense mRNA
with IGFBP-3 levels at 527 ng ml
71 (data not shown) and this
appeared to correspond to a small increase in cell death with the
sense mRNA (Figure 7E).
DISCUSSION
In addition to being key modulators of IGF-actions, accumulating
evidence suggests that the IGFBPs play an important role in the
regulation of both cell growth and death, independently of their
interaction with the IGFs. Growth inhibition by IGFBP-3 has been
reported in many cell lines such as Hs578T and MCF-7 breast
cancer cells (Colston et al, 1998; Oh et al, 1993a). In the normal
breast epithelial cell line, MCF-10A, it was recently reported that
IGFBP-3 at 30 ng ml
71 also induced growth inhibition (Martin
and Baxter, 1999). In other cell lines such as human airway smooth
muscles cells and colon cancer cells, IGFBP-3 has been shown to
act as a potent proliferative agent (Cohen et al, 2000; Kansra et
al, 2000). We determined that IGFBP-3 has differential effects on
cell growth in the MCF-10A cell line. We conﬁrmed that IGFBP-
3 did inhibit cell growth at low concentrations but further deter-
mined that at higher concentrations IGFBP-3 actually promoted
cell growth. These actions of IGFBP-3 were IGF-independent as
the presence of an IGF-I receptor antagonist had no effect and
the SPD synthetic IGFBP-3 fragment (which does not bind to
IGFs) was also able to mimic the differential effects on cell growth
exhibited by the intact IGFBP-3. The biphasic response of MCF-
10A cells to IGFBP-3 is interesting in relation to potential mechan-
isms of action, but in vivo the prevailing high (microgram) levels of
IGFBP-3 would imply that only the growth promoting action will
be relevant.
In the Hs578T cell line, it has been shown that TGF-b-induced
growth inhibition occurs at least partly through the increased
production of IGFBP-3 (Oh et al, 1995). We also conﬁrmed that
TGF-b-induced growth inhibition of Hs578T cells was accompa-
nied by an increase in IGFBP-3 production. We further
determined that TGF-b also induced growth inhibition in the
MCF-10A cells, but in contrast to the Hs578T cells, this was
accompanied by a decrease in the levels of IGFBP-3. The addition
of exogenous ngIGFBP-3 to MCF-10A cells partially overcame this
growth inhibitory effect of TGF-b. This suggested that the growth
inhibition induced by TGF-b in the MCF-10A cells was at least
partially mediated via a decrease in the production of IGFBP-3
and further conﬁrmed that IGFBP-3 can act as a potent prolifera-
tive agent in these normal breast epithelial cells. In addition to the
opposite actions of IGFBP-3 on these two cells lines, there appears
to be a big difference in sensitivity to IGFBP-3. A similar degree of
growth inhibition over the same dose range of TGF-b was seen
with a change in IGFBP-3 concentration of around 50 ng ml
71
in the MCF-10A cells but a change of around 600 ng ml
71 in
the Hs578T cells.
We have demonstrated previously that IGFBP-3 alone, in the
Hs578T cells, had no effect on cell death but accentuated C2-
induced apoptosis (Gill et al, 1997). In the MCF-10A cells
IGFBP-3 alone had no effect on cell death, but in direct contrast,
it conferred survival and reduced C2-induced apoptosis. Further-
more by depleting IGFBP-3 with TGF-b in the MCF-10A cells,
we found that cells were more susceptible to ceramide-induced cell
death. These data are consistent with IGFBP-3 acting as a survival
agent in this cell line.
We also investigated the effects of TGF-b-induced IGFBP-3 on
C2-induced death in the Hs578T breast cancer cells. In contrast to
adding IGFBP-3, we found that as opposed to accentuating, addi-
tion of TGF-b negated C2-induced cell death. These data reveal
that IGFBP-3 can have differential effects on cell death in the
Hs578T cells. We have previously shown that IGFBPs have differen-
tial effects on cell attachment depending upon the extracellular
matrix (ECM) component to which the cells are exposed. While
IGFBP-5 could enhance cell attachment to a general ECM, it
reduced attachment to ﬁbronectin (McCaig et al, 2001). It is well
documented that TGF-b enhances the production of ECM compo-
nents such as ﬁbronectin (Reiss and Barcellos-Hoff, 1997) and it is
attractive to speculate that the reversal of the effects of IGFBP-3 on
cell survival following TGF-b pre-treatment, may similarly be related
to an alteration in the compliment of ECM components. A funda-
mental difference between breast tumour cells and normal breast
epithelial cells is the acquisition of anchorage independence; the
transformed cell becomes less dependent upon the cues from the
tissue structural microenvironment (Schmeichel et al, 1998; Chrenek
et al, 2001). It is again attractive to speculate that the different effects
of IGFBP-3 on these two breast epithelial cell lines may be related to
differences in their dependence upon ECM-integrin induced intra-
cellular signals. This clearly warrants further investigation.
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Figure 8 The effects of TGF-b on the production of IGFBP-3 in the
normal breast epithelial cell line, MCF-10A and in the Hs578T breast can-
cer cell line in order to achieve growth inhibition.
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differential effects on normal versus breast cancer epithelial cells.
In the normal breast epithelial cells, IGFBP-3 is a potent survival
factor and proliferative agent, while in the cancer cells, IGFBP-3 is
an inhibitor of cell growth and accentuates cell death triggered by
various agents. Consequently TGF-b-induced growth inhibition in
Hs578T and MCF-10A cells is facilitated in a different way by up-
regulation or down-regulation of IGFBP-3 respectively (Figure 8).
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